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gmail.coAbstract Purpose: Fibrolamellar hepatocellular carcinoma (FL-HCC) and conventional
hepatocellular carcinoma (HCC) cases in two consecutive paediatric HCC trials were analysed
to compare outcome and derive treatment implications.
Patients and methods: Data of 24 FL-HCC (24% PRETEXT IV) and 38 HCC (42% PRE-
TEXT IV) cases from SIOPEL-2 and -3 (1995–1998, 1998–2006) were analysed. Patients were
treated according to SIOPEL-2 and -3 high-risk protocol (carboplatin + doxorubicin alternat-
ing with cisplatin; seven preoperative, three postoperative cycles) or with primary surgery
followed by chemotherapy as indicated.lsevier Ltd. All rights reserved.
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Antineoplastic agentsResults: Thirteen of 24 FL-HCC (54%) and 32/38 HCC (84%) were initially treated with che-
motherapy. Eight FL-HCC (33%) and ﬁve HCC patients (13%) had primary surgery. Partial
response was observed in 31% of FL-HCC versus 53% of HCC patients (p = 0.17). Complete
resection was achieved in ten FL-HCC and seven HCC patients (p = 0.08). Three-year event
free survival (EFS) was 22% for FL-HCC versus 28% for HCC. Overall survival (OS) was not
signiﬁcantly different at 3 years follow up (42% for FL-HCC versus 33% for HCC, p = 0.24).
EFS/OS Kaplan–Meier curves did not differ signiﬁcantly, with median follow up of 43
(FL-HCC) and 60 (HCC) months. No signiﬁcant correlation was found between potential
prognostic factors and OS. In the entire cohort nine out of 23 (39%) patients with complete
resection or orthotopic liver transplantation versus 34/39 (87%) without successful surgical
treatment, died.
Conclusions: Long-term OS in FL-HCC and HCC is similar. With low response rates, com-
plete resection remains the treatment of choice.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Fibrolamellar hepatocellular carcinoma (FL-HCC),
a rare variant of conventional hepatocellular carcinoma
(HCC), was ﬁrst described by Edmondson in 1956 and
accounts for approximately 5% of HCC cases.1,2 The
tumour is composed of large polygonal cells with large
nuclei containing marginalized chromatin and promi-
nent nucleoli and eosinophilic cytoplasm containing
pale bodies, and hyaline globules, surrounded by dis-
tinctly lamellar stroma.2,3 It is most common in the
age group between 5 and 35 years.3–7 Some studies
report a female predilection.4,6,8 Generally no underly-
ing liver disease including cirrhosis is present in FL-
HCC patients and in particular no link with hepatic
viruses has been established.2,9–12 While HCC is often
multifocal and metastatic at diagnosis and associated
with abdominal pain, FL-HCC is reputed to present
as a single, large, slow-growing, painless mass.6,11,13
Serum a-fetoprotein (AFP) levels are almost always
normal in patients with FL-HCC.2,5 The standard
treatment when possible is surgery with lymphadenec-
tomy, as FL-HCC is associated with a high rate of
lymph node metastasis and lymph nodes are common
sites of ﬁrst disease recurrence.11,14,15 Although FL-
HCC is often diagnosed at a stage that would not allow
for resection of HCC, aggressive resection may result in
long-term survival.11,13 Currently available non-surgical
treatments are relatively ineﬀective. Earlier studies con-
sistently reported a better prognosis of FL-HCC com-
pared to HCC.3,4,9,8,16,17 However, these studies lack
accompanying analyses of non-cirrhotic HCC cases,
and reported better outcomes of FL-HCC in adults
may be confounded by absence of cirrhosis, a separate
mortality risk factor in HCC.2,5,6,18 Since the majority
of reports regarding FL-HCC involves adult patients
only, analysis of the paediatric experience in the SIO-
PEL-2 and -3 trials and treatment recommendations
based on observations derived from these trials seemed
warranted.2. Patients and methods
2.1. Patients
Amongst 90 HCC patients registered in the SIOPEL
database, only cases with a clear distinction in histolog-
ical features during pathology review were selected in
order to compare two well-deﬁned groups of pathology
proven FL-HCC and HCC. Sixty-two patients with
either HCC (n = 38) or FL-HCC (n = 24) were selected
from the SIOPEL-2 and -3 databases for analysis. An in
depth analysis of the entire HCC group was performed
separately.
SIOPEL-2 and -3 were international, prospective,
cooperative clinical trials, open to registration of paedi-
atric patients with primary liver tumours between Octo-
ber 1995 and May 1998 and June 1998 and December
2006, respectively.19,20
2.2. Patient information at diagnosis and pre-treatment
extent of disease (PRETEXT) evaluation
Diagnostic biopsy of the primary tumour was man-
datory in children (a) younger than 6 months, (b) older
than 3 years or (c) with a normal serum AFP. In all
other cases biopsy was strongly recommended. Tumour
extension was assessed by computed tomography (CT)
or magnetic resonance imaging (MRI) for the abdomen,
and X-ray and CT for the intra-thoracic lesions.
Tumour stage was established with the PRE-Treatment
EXTent of disease (PRETEXT) system, based on ﬁnd-
ings at diagnostic imaging.21,22 Trials were approved
by the institutional review boards of participating cen-
tres. Informed consent was obtained from patients and
parents according to local requirements.
2.3. Treatment
All HCC cases (including FL-HCC) were classiﬁed as
high risk. The SIOPEL-2 and -3 high risk regimen
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boplatin/doxorubicin (CARBO/DOXO; preoperatively,
n = 7; postoperatively, n = 3) and delayed tumour resec-
tion.19,20 Patients were initially treated with alternating
courses of CDDP on days 1, 29, 57 and 85 and the com-
bination CARBO/DOXO on days 15, 43 and 71. CDDP
was administered at a dose of 80 mg/m2 IV over 24 h
followed by IV hydration. CARBO was given at
500 mg/m2 IV over 1 h, followed by DOXO 60 mg/m2
over 48 h. After seven courses, tumour resection was
performed if feasible. After resection patients received
the remaining three courses and ﬁnished treatment. If
after seven courses the tumour remained unresectable,
patients were treated with another three courses and, if
feasible, resection was performed. For those patients
who responded to chemotherapy, but whose primary
tumour remained unresectable, total hepatectomy with
orthotopic liver transplantation (OLT) was considered
at this point. If resection or OLT was performed after
10 courses, no postoperative chemotherapy was given.
In patients with initial metastatic disease, residual
lesions after pre-operative chemotherapy were removed
surgically, if feasible. As it became apparent during SIO-
PEL-1 that children with HCC had a lower response to
chemotherapy than children with hepatoblastoma,
clinicians were given the choice to follow the strategy
as outlined above or attempt surgery ﬁrst, followed by
post-operative chemotherapy using a more intensive
three-drug-regimen (CDDP and CARBO/DOXO –
‘SUPERPLADO’).23
2.4. Outcome deﬁnitions and statistical methods
Main objective of the original HCC study of which
the present study was derived, was to compare response
and subsequent resectability between an intensive multi-
agent chemotherapy regimen and earlier used chemo-
therapy regimens in paediatric patients with HCC. The
objectives of this analysis were to compare clinical
course and outcome of FL-HCC versus HCC in the
SIOPEL experience and to deﬁne implications on treat-
ment guidelines for FL-HCC. With regard to these
objectives, main outcome end-points were partial
response to preoperative chemotherapy, the rate of com-
plete resection, event free survival (EFS) and overall sur-
vival (OS). For FL-HCC, a partial response was deﬁned
as any tumour volume shrinkage. For HCC, a decrease
in AFP value >1 log below the original measurement
with or without volume change was considered a partial
response. Complete resection was deﬁned as resection
without microscopic residual disease of all tumour sites
based on pathological ﬁndings. EFS was deﬁned as the
time interval from date of diagnosis to ﬁrst occurrence
of progression, relapse or death from any cause, or the
date of last follow-up. OS was deﬁned as the time inter-
val between date of diagnosis and date of death from
any cause or date of last follow-up.Statistics of diﬀerences in patient characteristics
between groups were calculated using Wilcoxon test
(age and serum AFP), chi square test (PRETEXT clas-
siﬁcation) and Fisher’s exact test (all other patient char-
acteristics). The Kaplan–Meier method was used to
derive survival curves. Estimates of EFS and OS were
compared at 3 years by a z-test for the comparison of
proportions; the log rank test was deemed inappropriate
due to crossing curves. Multivariate proportional haz-
ards regression was performed to evaluate prognostic
factors for OS and EFS, stratiﬁed by histology. Back-
ward elimination was used to identify a parsimonious
model. All statistical evaluations were done with SAS
version 9.1.
3. Results
3.1. Patient and tumour characteristics
During SIOPEL-2 and SIOPEL-3, 62 cases of HCC
could be subdivided into HCC and FL-HCC. Of these
tumours, 24 (39%) had FL-HCC histology and 38
(61%) were consistent with HCC. The majority of
reviewed cases developed in normal liver (n = 58,
94%). An overview of demographic and clinical charac-
teristics is shown in Table 1.
3.2. Treatment
3.2.1. Chemotherapy
In total, 13 FL-HCC patients (54%) and 32 HCC
patients (84%) had documented preoperative chemo-
therapy. Partial tumour response to preoperative che-
motherapy occurred in four out of 13 (31%) patients
with FL-HCC versus 17/32 (53%) of patients with
HCC; the diﬀerence is not statistically signiﬁcant
(p = 0.17). Four FL-HCC patients received postopera-
tive chemotherapy only. Detailed response data are
shown in Table 2.
3.3. Surgery
Primary surgery was performed in eight (33%) FL-
HCC and ﬁve (13%) HCC patients. A correlation
between tumour size and complete resection rate or
EFS/OS could not be established in these patient sub-
groups. Of all patients who underwent surgery, either ini-
tially or delayed, ten FL-HCC patients (42%) and seven
HCC (18%) patients had a complete resection
(p = 0.08). Speciﬁc data on resection are summarised in
Table 3.
3.4. Outcome/survival
There is no statistically signiﬁcant diﬀerence in EFS
between the FL-HCC and HCC groups at 3 years follow
up (22% versus 28%, p = 0.30; Fig. 1). Multivariate
Table 1
Demographic and clinical characteristics ﬁbrolamellar hepatocellular
carcinoma (FL-HCC) group versus conventional hepatocellular carci-
noma (HCC) group.
Patient characteristics FL-HCC
(n = 24)
HCC (n = 38) p-value
Age (months, median,
range)
170 (95–190) 110 (1–207) p = 0.0002
Age > 12 years 88% 29% p < 0.0001
Sex M:F 54:46% 47:53% p = 0.79
HbsAg positive 0 (0%) 2 (5%)
Liver disease:
hepatitis B
0 (0%) 1 (3%)
Liver disease:
cirrhosis n.o.s.
0 (0%) 1 (3%)
AFP (median,
range) ng/mL
4 (1–44,790) 211,375 (1–
1,700,000)
p = 0.0001
AFP < 100 ng/mL 91% 14% p < 0.0001
AFP unknown 1 (4%) 2 (5%)
PRETEXT I 4 (17%) 0 (0%)
PRETEXT II 10 (42%) 9 (24%)
PRETEXT III 5 (21%) 13 (34%)
PRETEXT IV 5 (21%) 16 (42%)
PRETEXT overall p = 0.013
V+ 3 (13%) 7 (18%) p = 0.73
P+ 2 (8%) 15 (39%) p = 0.02
E+ 10 (42%) 7 (18%) p = 0.04
Focality: solitary 17 (71%) 14 (37%)
Focality: multiple 6 (25%) 22 (58%)
Focality overall p = 0.015
Focality unknown 1 (4%) 2 (5%)
Metastasis 10 (42%) 11 (29%) p = 0.028
Abbreviations:HbsAg, hepatitis B surface antigen; n.o.s., not otherwise
speciﬁed; AFP, a-fetoprotein; PRETEXT, Pre-Treatment EXTension;
V+, P+, vascular invasion (three hepatic veins or portal vein, respec-
tively); E+, intra-abdominal extrahepatic extension.
Table 2
Response to preoperative chemotherapy by histology type.
Response FL-HCC HCC Total
Partial response 4/13 (31%) 17/32 (53%) 21
Stable disease 6/13 (46%) 4/32 (13%) 10
Progressive disease 1/13 (8%) 7/32 (22%) 8
Not evaluable 1/13 (8%) 1/32 (3%) 2
Lost to follow up 1/13 (8%) 1/32 (3%) 2
Early death 0/13 (0%) 2/32 (6%) 2
Total 13 32 45
Abbreviations: FL-HCC, ﬁbrolamellar hepatocellular carcinoma;
HCC, conventional hepatocellular carcinoma.
Table 3
Surgical data by histology type.
Resection status FL-HCC HCC Total
Complete resection 10/24 (42%) 7/38 (18%) 17
Initial resection 6/24 (25%) 2/38 (5%) 8
Delayed resection 4/24 (17%) 5/38 (13%) 9
Microresidual disease 1/24 (4%) 5/38 (13%) 6
Initial resection 0/24 (0%) 1/38 (3%) 1
Delayed resection 1/24 (4%) 4/38 (11%) 5
Incomplete resection 1/24 (4%) 1/38 (3%) 2
Initial resection 1/24 (4%) 0/38 (0%) 1
Delayed resection 0/24 (0%) 1/38 (3%) 1
Unresectable 1/24 (4%) 2/38 (5%) 3
OLT 1/24 (4%) 5/38 (13%) 6
Initial resection 0/24 (0%) 1/38 (3%) 1
Delayed resection 1/24 (4%) 4/38 (11%) 5
Postoperative death 1/24 (4%) 0/38 (0%) 1
No surgery, alive 0/24 (0%) 1/38 (3%) 1
No surgery, death 6/24 (25%) 14/38 (37%) 20
Not evaluable 3/24 (13%) 3/38 (8%) 6
Initial resection 1/24 (4%) 1/38 (3%) 2
Delayed resection 2/24 (8%) 2/38 (5%) 4
Total 24 38 62
Abbreviations: FL-HCC, ﬁbrolamellar hepatocellular carcinoma;
HCC, conventional hepatocellular carcinoma; OLT, orthotopic liver
transplantation.
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stratiﬁed by histology showed a trend towards lower
EFS with multifocality (HR 1.74, p = 0.09) and with
age above 12 years (HR 1.89, p = 0.07). OS was better
for FL-HCC during the ﬁrst 3 years. At 3 years, OS
was 42% for FL-HCC versus 33% for HCC (p = 0.24).
Forty-two per cent of patients with HCC versus 2% with
FL-HCC died within 1 year. However, thereafter the
Kaplan–Meier curves crossed and the FL-HCC curve
reached a plateau phase lower than observed in HCCafter approximately 4 years follow up (Fig. 2). The med-
ian follow up was 43 months (range 1–117 months) in
the FL-HCC group and 60 months (range 9–114
months) in the HCC group. No signiﬁcant correlation
was found between potential prognostic factors and
OS. Of the 23 patients who had a complete resection
or an OLT, nine died (39%), whereas 34/39 (87%) of
those without a documented complete resection died.4. Discussion
In contrast to earlier study reports, our study shows
that the long-term outcome in FL-HCC patients does
not diﬀer from that of HCC patients3,4,9,8,16,17 In line
with this analysis, a Children’s Oncology Group
(COG) study found similar prognoses for the two sub-
types, treated according to the same protocol.7 Some
studies claim, however, that FL-HCC has a survival
advantage in high stages and transplanted cases
only.13,24 Several other recent papers also report that
FL-HCC is an aggressive tumour, which has no better
outcome than HCC on behalf of tumour
characteristics.2,7,18
In our study OS in the FL-HCC group declined to
reach a plateau phase lower than for HCC. As such,
results from SIOPEL-1, where longer survival in the
same time range for FL-HCC patients compared to
HCC patients was observed, could not be recon-
ﬁrmed.25 The low number of patients with FL-HCC
may play a role, as only six out of 39 HCC patients
in that study had the FL-HCC variant. However,
although longer survival for FL-HCC patients was
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
months
%
 e
ve
nt
 fr
ee
0 12 24 36 48 60 72 84 96 108 120
FL-HCC  n = 24
HCC       n = 38
Fig. 1. Kaplan–Meier estimate of event free survival (EFS) for ﬁbrolamellar hepatocellular carcinoma (FL-HCC) group versus conventional
hepatocellular carcinoma (HCC) group. EFS FL-HCC versus HCC at 3 years follow-up was compared for proportions by z-test; p = 0.30.
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Fig. 2. Kaplan–Meier estimate of overall survival (OS) for ﬁbrolamellar hepatocellular carcinoma (FL-HCC) group versus conventional
hepatocellular carcinoma (HCC) group. OS FL-HCC versus HCC at 3 years follow up was compared for proportions by z-test; p = 0.24.
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a median survival of 15 months for all patients who
died in the study.
FL-HCC and HCC should be regarded as separate
entities, displaying distinctive pathological patterns
and dysregulated biological pathways. Molecular mark-
ers indicative of FL-HCC (CK7, EMA, mCEA, CA19-
9, EpCAM) indicate that this tumour could be derived
from a precursor cell with the ability to diﬀerentiate into
hepatocytes and biliary cells, unlike HCC that does not
express any of these markers.14 In contrast to HCC, FL-HCC does not show CTNNb or p53 mutations, how-
ever, high levels of Y654-b-catenin represent increased
receptor tyrosine kinase signalling, potentially rendering
FL-HCC susceptible to receptor tyrosine kinase target-
ing.26 In a recent report, more than 75% of investigated
FL-HCC’s showed overexpression of the oncogene
AGR2.27 Other potential molecular mechanisms include
activation of the NF-jB signalling pathway.28 The slow
proliferative rate of stem cells and high biliary and
hepatocytic diﬀerentiation phenotype of FL-HCC may
explain its relative resistance to chemotherapy and
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ﬁndings of molecular markers in FL-HCC may pave
the way for targeted therapy.
Clinically, children with FL-HCC in this series
tended to be older at diagnosis than those with HCC,
in line with ﬁndings in the prospective COG study,
where 90% of children with FL-HCC versus 47% with
HCC were above 10 years of age (Table 1).7 The female
predilection identiﬁed in reports of mostly adult patients
was not reproduced in our paediatric series (M:F
54:46%, Table 1), conﬁrming results of other paediatric
and mixed paediatric/adult series.3,4,6–8,10,12 Similar to
ﬁndings in other reports, AFP levels were low in FL-
HCC cases (median 4 ng/mL; range 1–44,790 ng/mL)
in comparison to HCC cases (median 211,375 ng/mL;
range 1–1,700,000).5–7,10,11 FL-HCC was less often mul-
tifocal than HCC (Table 1). The presence of satellite
lesions correlated, albeit borderline, with reduced
EFS in the multivariate analysis of the entire group, in
line with a series of 174 HCC’s of which 15 were of
FL-HCC histology (average age FL-HCC patients
23 ± 2.6 years), where absence of multiple tumours
was signiﬁcantly associated with increased survival.6
Importantly, stage at diagnosis may have had an eﬀect
on diﬀerences in outcome between groups; HCC was
more often diagnosed as PRETEXT III, IV or P+. On
the other hand, FL-HCC was more frequently PRE-
TEXT E+ (Table 1). However, no signiﬁcant correlation
between any potential prognostic factors and OS was
found.
In the present study, both groups were treated with
the same chemotherapy regimen and there was only a
borderline diﬀerence in the overall low rate of partial
response to preoperative chemotherapy (31% of treated
FL-HCC’s versus 55% of HCC’s), possibly reﬂecting
resistance to currently used therapies in either type of
histology.
FL-HCC is commonly described as more suitable for
resection than HCC, and complete resection including
lymph node dissection is at present the most eﬀective
treatment option.11,13 In contrast to ﬁndings in the
large, prospective, uniformly treated COG series, our
study found a higher complete resection rate in the
FL-HCC group, despite a higher number of OLT in
the HCC group.7 In the entire cohort, the percentage
of death was much higher amongst patients who did
not have a complete resection or OLT versus patients
who did undergo successful surgical treatment, stressing
the importance of a complete resection in either tumour
type. The higher survival rate at early follow up in the
FL-HCC group may have its origins in the observed
higher complete resection rate. Another potential expla-
nation for the delayed decline in survival in this group
compared to the HCC group is late recurrence, a well-
known feature of FL-HCC.11,13 The combination ofan (on average) earlier stage at diagnosis and more
extrahepatic intra-abdominal metastasis, together with
ﬁndings of inferior long term outcome in FL-HCC com-
pared to HCC emphasises the importance of a radical
surgical approach – resection or OLT – at the earliest
opportunity in FL-HCC. Probably in children the
Milano criteria should not even be taken into account.29
Repeat resection for recurrence is strongly advocated by
some, given the lack of good alternative treatment strat-
egies and the relatively indolent tumour behaviour
which may be associated with low sensitivity to other
therapies.7,11 As repeat resection for FL-HCC has not
been investigated by SIOPEL, no recommendation on
this subject can be derived from this study.
This is the largest available prospective study com-
paring FL-HCC and HCC in children. Except for data
from the COG study, currently available knowledge of
behaviour and treatment of this rare tumour is derived
from small, mostly retrospective series, with multiple
treatment modalities, inconsistent clinical detail, and
varying patient age.7 Thus, comparing these studies is
of limited value.
Results from the present study conﬁrm the conclu-
sion of recent studies that FL-HCC does not have a
more favourable prognosis than HCC.7,18 A long follow
up is warranted given the late recurrences observed.
Given the low response to chemotherapy and since long
term survival is only seen in completely resected FL-
HCC patients, complete resection should be pursued
whenever possible. When FL-HCC is diagnosed through
biopsy, primary surgery can be performed. Multicentre
prospective randomized trials are needed to test new
treatment modalities and regimens toward eﬃcacious
therapies, especially in advanced disease. The COG,
SIOPEL, Gesellschaft fu¨r Pa¨diatrische Onkologie und
Ha¨matologie (GPOH) and Japanese Study for Paediat-
ric Liver Tumours (JPLT) started the Children’s Hepatic
tumour International Collaboration (CHIC) Project, an
international hepatic tumours database.30 This initiative
serves to identify independent prognostic factors, and
allows for development of a common risk stratiﬁcation
system and common chemotherapy response criteria
for the development of therapeutic trials. Despite its ret-
rospective nature, this collaboration holds promise to
advance our knowledge and improve treatment of FL-
HCC, as its comprehensive nature may overcome the
issues of low numbers in uniformly treated series of this
rare but detrimental tumour.
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